biguanides has been researched along with Metabolic Syndrome in 10 studies
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.
biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A multivariate analysis with multiple logistic regression revealed that visceral fat accumulation was inhibited in women and those taking statins or thiazolidines and aggravated in men and those with obesity or an increased waist circumference." | 3.80 | Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes. ( Ichikawa, T; Kohno, S; Nakao, K; Onitsuka, Y; Takeshima, F, 2014) |
| "Nonalcoholic steatohepatitis (NASH) once considered a benign process is now known to lead to progressive fibrosis and cirrhosis." | 2.43 | [Drug therapy for non-alcoholic steatohepatitis]. ( Hibi, T; Tomita, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dvorácskó, S | 1 |
| Herrerias, A | 1 |
| Oliverio, A | 1 |
| Bhattacharjee, P | 1 |
| Pommerolle, L | 1 |
| Liu, Z | 1 |
| Feng, D | 1 |
| Lee, YS | 1 |
| Hassan, SA | 1 |
| Godlewski, G | 1 |
| Cinar, R | 1 |
| Iyer, MR | 1 |
| Wang, C | 1 |
| Niederstrasser, H | 1 |
| Douglas, PM | 1 |
| Lin, R | 1 |
| Jaramillo, J | 1 |
| Li, Y | 1 |
| Oswald, NW | 1 |
| Zhou, A | 1 |
| McMillan, EA | 1 |
| Mendiratta, S | 1 |
| Wang, Z | 1 |
| Zhao, T | 1 |
| Lin, Z | 1 |
| Luo, M | 1 |
| Huang, G | 1 |
| Brekken, RA | 1 |
| Posner, BA | 1 |
| MacMillan, JB | 1 |
| Gao, J | 1 |
| White, MA | 1 |
| Herrera-Martínez, AD | 1 |
| Pedraza-Arevalo, S | 1 |
| L-López, F | 1 |
| Gahete, MD | 1 |
| Gálvez-Moreno, MA | 1 |
| Castaño, JP | 1 |
| Luque, RM | 1 |
| Onitsuka, Y | 1 |
| Takeshima, F | 1 |
| Ichikawa, T | 1 |
| Kohno, S | 1 |
| Nakao, K | 1 |
| Takahashi, T | 1 |
| Odawara, M | 2 |
| Kotake, H | 1 |
| Tomita, K | 1 |
| Hibi, T | 1 |
| Suzuki, T | 1 |
| Miwa, T | 1 |
| Notoya, Y | 1 |
| Batsis, JA | 1 |
| Nieto-Martinez, RE | 1 |
| Lopez-Jimenez, F | 1 |
| Jellinger, PS | 1 |
6 reviews available for biguanides and Metabolic Syndrome
| Article | Year |
|---|---|
[Biguanides].
Topics: Biguanides; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Metabolic Syndrome | 2011 |
[Syndrome X].
Topics: Animals; Bezafibrate; Biguanides; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hyperinsulinism | 2002 |
[Drug therapy for non-alcoholic steatohepatitis].
Topics: Antihypertensive Agents; Antioxidants; Biguanides; Fatty Liver; Humans; Hypolipidemic Agents; Insuli | 2006 |
[Biguanides].
Topics: Biguanides; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin | 2006 |
Metabolic syndrome: from global epidemiology to individualized medicine.
Topics: Anti-Obesity Agents; Bariatric Surgery; Biguanides; Body Mass Index; Caloric Restriction; Cardiovasc | 2007 |
Metabolic consequences of hyperglycemia and insulin resistance.
Topics: Biguanides; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Dyslipidemias; Fatty Acids, No | 2007 |
4 other studies available for biguanides and Metabolic Syndrome
| Article | Year |
|---|---|
Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders.
Topics: AMP-Activated Protein Kinases; Animals; Biguanides; Cannabinoid Receptor Antagonists; Cannabinoids; | 2023 |
Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.
Topics: Animals; Autophagosomes; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Big | 2017 |
Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
Topics: Adult; Aged; Apoptosis; Biguanides; Carcinoid Tumor; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2019 |
Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes.
Topics: Aged; Biguanides; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Diet, Western; Femal | 2014 |